Professor of Medicine, Jefferson Medical College
Oncology
Dr. Russell Schilder, MD
|
|
Give Review
Dr. Russell Schilder is an expert in the field of Oncology. He studied medicine at University of Miami Miller School of Medicine. University of Miami Miller School of Medicine is ranked 45 in research and 0 in primary care medicine He has 6 awards "Patient-Centered Specialty Practice Recognition Program", "America's Top Doctors", "Philadelphia Magazine", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Russell Schilder is a published doctor as well. He has 39 publications published. The latest was: A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. He accepts all Medicare patients.
Publications
- A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.
- A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal Carcinoma: A Gyneco...
- A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial Cancer: A Gynecologic Oncology Group study.
- Aurora kinase A mediates epithelial ovarian Cancer cell migration and adhesion.
- A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal Carcinomas: A Gynecologic Oncol...
- Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal Carcinoma: A Gynecologic Oncology Group study.
- Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and pr...
- A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary p...
- Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated Cancers of the cervix and evaluation of epidermal growth factor receptor immu...
- Epithelial ovarian Cancer.
- A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal Cancer: a Gynecol...
- mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell Carcinoma of the ovary.
- A phase II trial of erlotinib in recurrent squamous cell Carcinoma of the cervix: a Gynecologic Oncology Group Study.
- Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal Carcinoma with the potential for dose escala...
- Management of recurrent ovarian Carcinoma: current status and future directions.
- A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube Cancer.
- Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal Carcinoma: a Gynecologic Oncology Group S...
- Platinum resistance: the role of DNA repair pathways.
- Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma.
- RAD001 inhibits human ovarian Cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian Cancer model.
- Long-term responses in patients with recurring or refractory B-cell non-Hodgkin Lymphoma treated with yttrium 90 ibritumomab tiuxetan.
- Novel non-cytotoxic therapy in ovarian Cancer: current status and future prospects.
- Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian Cancer: potential predictive relationship with tumor HER2 activation st...
- Chronic myelogenous Leukemia.
- Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal Carcinoma and evaluation of epidermal growth factor receptor mutation...
- Imatinib mesylate and its potential implications for gynecologic Cancers.
- Evaluation of gemcitabine in previously treated patients with non-squamous cell Carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
- AntiLymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's Lymphoma: a review of the literature.
- Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's Lymphoma.
- Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial Carcinoma: A phase II study of the Gynecologic Oncology Group.
- Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell Lymphoma: long-term follow-up of a phase 1/2 study.
- Focus on epithelial ovarian Cancer.
- Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
- Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's Lymphoma and mild thrombocytopenia.
- Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovar...
- Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin Lymphoma and mild thrombocytopenia: a phase II multicenter trial.
- Refractory fallopian tube Carcinoma - current perspectives in pathogenesis and management.
- Influence of bevacizumab on vaginal cuff evisceration eight months after ovarian Cancer cytoreduction surgery: A case report.
Schools
University Of Miami School Of Medicine
Temple University Hospital
Fox Chase Cancer Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Personal Choice PPO
- Regional Pref Network EPO
- Regional Pref Network HMO
- Regional Pref Network HMO+
- Regional Pref Network POS+
- Regional Pref Network PPO
- Blue Cross Blue Shield
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health America PPO
- Coventry Health Care of Delaware PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- Harvard Pilgrim Health Care PPO
- Direct Access
- Horizon Blue Cross Blue Shield HMO
- Horizon Blue Cross Blue Shield POS
- Horizon Blue Cross Blue Shield PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- QualCare HMO
- QualCare PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Patient-Centered Specialty Practice Recognition Program
- America's Top Doctors
- Philadelphia Magazine
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
Fox Chase Cancer Center -
Temple University Hospital -
University of Miami Miller School of Medicine
Hospital
-
Fox Chase Cancer Center-American Oncologic Hospital -
Thomas Jefferson University Hospital
Drug Facts
| NPI NUMBER | 1699797860 | |
| NPPES Provider LastName | SCHILDER | |
| NPPES Provider FirstName | RUSSELL | |
| NPPES Provider ZIPCode | 191074216 | |
| NPPES Provider State | PA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 40.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1699797860 |
| Last Name Of The Provider | SCHILDER |
| First Name Of The Provider | RUSSELL |
| View All |
Similar Doctors
|
Dr. Ping Gong, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen J. Bagley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tal Z. Zaks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ranee Mehra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul F. Engstrom, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Bruce M. Boman, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Vikram R. Paralkar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Agata M. Bogusz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel G. Haller, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Tami Bach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marlise R. Luskin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ursina R. Teitelbaum, MD
This Doctor is OpenDoctor Recommended.
|